BFS
SUPN icon

Bare Financial Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Bare Financial Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.12K Buy
110
+21
+24% +$1.01K ﹤0.01% 842
2026
Q1 		$4.6K Buy
89
+49
+123% +$2.5K ﹤0.01% 689
2025
Q4 		$1.99K Buy
40
+10
+33% +$486 ﹤0.01% 872
2025
Q3 		$1.43K Buy
30
+15
+100% +$604 ﹤0.01% 910
2025
Q2 		$473 Buy
+15
New +$481 ﹤0.01% 1151

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Bare Financial Services's SUPN Position: Q2 2026 in Review

Bare Financial Services increased its Supernus Pharmaceuticals (SUPN) stake by 24% in Q2 2026, buying an estimated $1.01K and bringing the position to 110 shares worth $5.12K. The position accounts for ﹤0.01% of the portfolio, ranked #842.

Bare Financial Services first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Bare Financial Services held 110 shares of Supernus Pharmaceuticals worth $5.12K as of Q2 2026.
  • Bare Financial Services bought 21 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.01K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #842 holding.
  • Bare Financial Services first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.